Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Voyager Therapeutics stock | 8.74

Own Voyager Therapeutics stock in just a few minutes.

Posted

Fact checked

Voyager Therapeutics, Inc is a biotechnology business based in the US. Voyager Therapeutics shares (VYGR) are listed on the NASDAQ and all prices are listed in US Dollars. Voyager Therapeutics employs 185 staff and has a trailing 12-month revenue of around USD$99.9 million.

How to buy shares in Voyager Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Voyager Therapeutics. Find the stock by name or ticker symbol: VYGR. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Voyager Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$8.74, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Voyager Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Voyager Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Voyager Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Voyager Therapeutics's share price has had significant negative movement.

Its last market close was USD$8.74, which is 31.34% down on its pre-crash value of USD$12.73 and 39.62% up on the lowest point reached during the March crash when the shares fell as low as USD$6.26.

If you had bought USD$1,000 worth of Voyager Therapeutics shares at the start of February 2020, those shares would have been worth USD$614.49 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$743.86.

Voyager Therapeutics share price

Use our graph to track the performance of VYGR stocks over time.

Voyager Therapeutics shares at a glance

Information last updated 2020-10-14.
Latest market close USD$8.74
52-week range USD$6.26 - USD$15.81
50-day moving average USD$11.2589
200-day moving average USD$11.627
Wall St. target price USD$22.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.75

Buy Voyager Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Voyager Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Voyager Therapeutics price performance over time

Historical closes compared with the close of $8.74 from 2020-11-16

1 week (2020-11-15) N/A
1 month (2020-10-26) -20.90%
3 months (2020-08-22) N/A
6 months (2020-05-22) N/A
1 year (2019-11-22) N/A
2 years (2018-11-22) N/A
3 years (2017-11-22) N/A
5 years (2015-11-22) N/A

Voyager Therapeutics financials

Revenue TTM USD$99.9 million
Gross profit TTM USD$-15,344,000
Return on assets TTM -11.84%
Return on equity TTM -61.98%
Profit margin -60.61%
Book value $2.067
Market capitalisation USD$460.4 million

TTM: trailing 12 months

Shorting Voyager Therapeutics shares

There are currently 1.2 million Voyager Therapeutics shares held short by investors – that's known as Voyager Therapeutics's "short interest". This figure is 45.7% down from 2.2 million last month.

There are a few different ways that this level of interest in shorting Voyager Therapeutics shares can be evaluated.

Voyager Therapeutics's "short interest ratio" (SIR)

Voyager Therapeutics's "short interest ratio" (SIR) is the quantity of Voyager Therapeutics shares currently shorted divided by the average quantity of Voyager Therapeutics shares traded daily (recently around 270033.10344828). Voyager Therapeutics's SIR currently stands at 4.35. In other words for every 100,000 Voyager Therapeutics shares traded daily on the market, roughly 4350 shares are currently held short.

However Voyager Therapeutics's short interest can also be evaluated against the total number of Voyager Therapeutics shares, or, against the total number of tradable Voyager Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Voyager Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Voyager Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0454% of the tradable shares (for every 100,000 tradable Voyager Therapeutics shares, roughly 45 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Voyager Therapeutics.

Find out more about how you can short Voyager Therapeutics stock.

Voyager Therapeutics share dividends

We're not expecting Voyager Therapeutics to pay a dividend over the next 12 months.

Voyager Therapeutics share price volatility

Over the last 12 months, Voyager Therapeutics's shares have ranged in value from as little as $6.26 up to $15.81. A popular way to gauge a stock's volatility is its "beta".

VYGR.US volatility(beta: 1.8)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Voyager Therapeutics's is 1.7952. This would suggest that Voyager Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Voyager Therapeutics overview

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and alpha-synuclein program for synucleinopathies, Parkinson's disease, Lewy Body Dementia, and multiple system atrophy. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site